Right to Try Bills Push the Needle on Risk’ –  panel of experts, including WCGF Executive Director Marjorie A. Speers, discuss risks associated with Right-to-Try legislation

Right to Try Bills Push the Needle on Risk’ –  panel of experts, including WCGF Executive Director Marjorie A. Speers, discuss risks associated with Right-to-Try legislation

Published December 24, 2017 by OncLive

“Congressional “right-to-try” legislation could make investigational drugs available to desperately ill patients sooner in the trials process, but there are substantial risks, said a panel of experts at the Patient-Centered Oncology Conference, held November 16-17 in Philadelphia, Pennsylvania.

Earlier in the clinical trials process, less is known about the drugs, which may be highly toxic and may have no efficacy. Furthermore, the House of Representatives’ version of the bill would allow companies to charge any amount for access to their investigational drugs. That is a scary proposition due to the potential for cost exploitation, members of the panel said.”

You can read the full article from OncLive HERE

 

 

Comments

comments

2018-07-02T14:50:44+00:00December 24, 2017|News|